View More Recent Stories

Sep 18, 2024 04:04PM Ascendis Pharma (ASND) Announces Proposed Public Offering of ADSs
Sep 18, 2024 04:03PM Ascendis Pharma (ASND) Files Mixed Shelf
Sep 17, 2024 06:52AM Ascendis Pharma (ASND) PT Raised to $190 at Oppenheimer
Sep 17, 2024 06:32AM Ascendis Pharma (ASND) PT Raised to $205 at Evercore ISI
Sep 16, 2024 04:35PM Ascendis Pharma (ASND) PT Raised to $179 at Jefferies
Sep 16, 2024 03:08PM Barclays Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
Sep 16, 2024 02:58PM Ascendis Pharma (ASND) option IV flat as share price up 19.8%
Sep 16, 2024 12:07PM BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND), PT $175
Sep 16, 2024 12:06PM Ascendis Pharma (ASND) PT Raised to $200 at Goldman Sachs
Sep 16, 2024 10:25AM Stifel on Ascendis Pharma (ASND): 'A Clear Win Following Recent Commercial Setbacks'
Sep 16, 2024 08:38AM BioMarin Pharma (BMRN) Weakness Tied to Data From Ascendis Pharma (ASND)
Sep 16, 2024 07:01AM Ascendis Pharma (ASND) Reports Pivotal ApproaCH Trial of TransCon CNP Achieved Primary Objective
Sep 13, 2024 12:59PM Citi Reiterates Buy Rating on Ascendis Pharma (ASND)
Sep 13, 2024 08:32AM Ascendis Pharma (ASND) to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO
Sep 10, 2024 05:01AM Citi Opens 30-Day Upside Catalyst Watch on Ascendis Pharma (ASND)
Sep 6, 2024 09:09AM TD Cowen Reiterates Buy Rating on Ascendis Pharma (ASND)
Sep 5, 2024 06:54AM Oppenheimer Upgrades Ascendis Pharma (ASND) to Outperform
Sep 4, 2024 08:36AM Ascendis Pharma (ASND) PT Lowered to $157 at TD Cowen
Sep 4, 2024 07:44AM Goldman Sachs Reiterates Buy Rating on Royalty Pharma (RPRX)
Sep 4, 2024 05:18AM Ascendis Pharma (ASND) PT Lowered to $174 at Jefferies
Sep 4, 2024 05:06AM Ascendis Pharma (ASND) PT Lowered to $180 at Goldman Sachs
Sep 4, 2024 04:57AM Ascendis Pharma (ASND) PT Lowered to $178 at Citi
Sep 3, 2024 05:15PM Ascendis Pharma (ASND) Misses Q2 EPS by 55c; cuts Skytrofa revenue outlook
Sep 3, 2024 05:07PM Ascendis Pharma (ASND) and Royalty Pharma (RPRX) Enter $150M Royalty Funding Agreement
Aug 21, 2024 06:21AM Ascendis Pharma (ASND) PT Raised to $174 at JPMorgan
Aug 12, 2024 01:43PM Ascendis Pharma (ASND) PT Raised to $195 at Goldman Sachs
Aug 12, 2024 07:00AM Ascendis Pharma (ASND): FDA Approves YORVIPATH (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults
Aug 12, 2024 06:57AM Ascendis Pharma (ASND) Halted, News Pending
Jun 25, 2024 05:36AM TD Cowen Upgrades Ascendis Pharma (ASND) to Buy
Jun 13, 2024 05:55PM Ascendant Resources Announces Results of Annual General Meeting of Shareholders
Jun 13, 2024 05:55PM Ascendant Resources Announces Results of Annual General Meeting of Shareholders
Jun 13, 2024 05:55PM Ascendant Resources Announces Results of Annual General Meeting of Shareholders
Jun 12, 2024 05:58AM BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND)
View More Recent Stories